NASDAQ:CLDX

Celldex Therapeutics Stock Forecast, Price & News

$27.78
-0.22 (-0.79 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.80
$28.39
50-Day Range
$20.79
$31.44
52-Week Range
$9.59
$33.24
Volume1.19 million shs
Average Volume594,154 shs
Market Capitalization$1.10 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.05
30 days | 90 days | 365 days | Advanced Chart
Receive CLDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Celldex Therapeutics logo

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

381st out of 2,097 stocks

Diagnostic Substances Industry

6th out of 35 stocks

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

Is Celldex Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Celldex Therapeutics stock.
View analyst ratings for Celldex Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Celldex Therapeutics?

Wall Street analysts have given Celldex Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Celldex Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Celldex Therapeutics' next earnings date?

Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Celldex Therapeutics
.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.07. The biopharmaceutical company earned $0.69 million during the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 24.71% and a negative net margin of 1,184.99%.
View Celldex Therapeutics' earnings history
.

How has Celldex Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CLDX shares have increased by 1,268.5% and is now trading at $27.78.
View which stocks have been most impacted by COVID-19
.

When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work?

Celldex Therapeutics's stock reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CLDX?

3 equities research analysts have issued twelve-month target prices for Celldex Therapeutics' shares. Their forecasts range from $35.00 to $36.00. On average, they expect Celldex Therapeutics' share price to reach $35.50 in the next twelve months. This suggests a possible upside of 27.8% from the stock's current price.
View analysts' price targets for Celldex Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the following people:
  • Mr. Anthony S. Marucci, Founder, Pres, CEO & Director (Age 59, Pay $1.06M)
  • Dr. Tibor Keler, Founder, Chief Scientific Officer & Exec. VP (Age 62, Pay $654.91k)
  • Mr. Sam Martin, Sr. VP, CFO, Sec. & Treasurer (Age 50, Pay $542.07k)
  • Ms. Elizabeth Crowley, Chief Product Devel. Officer & Sr. VP (Age 49, Pay $507.24k)
  • Dr. Margo Heath-Chiozzi M.D., Sr. VP of Regulatory Affairs (Age 64, Pay $548.76k)
  • Ms. Sarah Cavanaugh, Sr. VP of Corp. Affairs & Admin. (Age 46)
  • Mr. Freddy A. Jimenez Esq., Sr. VP & Gen. Counsel (Age 52)
  • Dr. Ronald A. Pepin, Chief Bus. Officer & Sr. VP (Age 65)
  • Dr. Richard M. Wright Ph.D., Chief Commercial Officer & Sr. VP (Age 57)
  • Dr. Diane C. Young, Sr. VP & Chief Medical Officer (Age 64)

Who are some of Celldex Therapeutics' key competitors?

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.87%), Redmile Group LLC (8.55%), Acuta Capital Partners LLC (2.57%), Opaleye Management Inc. (2.49%), BlackRock Inc. (2.44%) and Octagon Capital Advisors LP (1.42%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin and Tibor Keler.
View institutional ownership trends for Celldex Therapeutics
.

Which institutional investors are selling Celldex Therapeutics stock?

CLDX stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Renaissance Technologies LLC, Polar Capital Holdings Plc, Octagon Capital Advisors LP, Sphera Funds Management LTD., Altium Capital Management LP, Goldman Sachs Group Inc., and Squarepoint Ops LLC.
View insider buying and selling activity for Celldex Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Celldex Therapeutics stock?

CLDX stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, RTW Investments LP, Millennium Management LLC, Pura Vida Investments LLC, Citigroup Inc., BlackRock Inc., Rafferty Asset Management LLC, and Barclays PLC. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin, and Tibor Keler.
View insider buying and selling activity for Celldex Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $27.78.

How much money does Celldex Therapeutics make?

Celldex Therapeutics has a market capitalization of $1.10 billion and generates $7.42 million in revenue each year. The biopharmaceutical company earns $-59,780,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.

How many employees does Celldex Therapeutics have?

Celldex Therapeutics employs 123 workers across the globe.

What is Celldex Therapeutics' official website?

The official website for Celldex Therapeutics is www.celldex.com.

Where are Celldex Therapeutics' headquarters?

Celldex Therapeutics is headquartered at 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]ldextherapeutics.com.


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.